Novel therapeutic agents for the treatment of diabetic kidney disease
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel therapeutic agents for the treatment of diabetic kidney disease
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume -, Issue -, Pages 1-17
Publisher
Informa UK Limited
Online
2020-08-19
DOI
10.1080/13543784.2020.1811231
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes
- (2020) Alessandro Doria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Allopurinol on the Progression of Chronic Kidney Disease
- (2020) Sunil V. Badve et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
- (2020) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
- (2019) Jonatan Barrera-Chimal et al. KIDNEY INTERNATIONAL
- GREATER COMBINED REDUCTIONS IN HBA1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VS COMPARATORS IN TYPE 2 DIABETES
- (2019) Helena W. Rodbard et al. Endocrine Practice
- Endothelial cells secreted endothelin-1 augments diabetic nephropathy via inducing extracellular matrix accumulation of mesangial cells in ETBR-/- mice
- (2019) Hong-hong Zou et al. Aging-US
- Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
- (2019) Hiddo J L Heerspink et al. LANCET
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes
- (2019) Daniël H. van Raalte et al. DIABETES CARE
- Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
- (2019) Milton Packer et al. EUROPEAN JOURNAL OF HEART FAILURE
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial
- (2019) Stefan D. Anker et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effects of Selonsertib in Patients with Diabetic Kidney Disease
- (2019) Glenn M. Chertow et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- The expanding résumé of SGLT2 inhibitors
- (2019) Ian H de Boer Lancet Diabetes & Endocrinology
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial
- (2019) M. Angelyn Bethel et al. DIABETES CARE
- Glycogen synthase kinase 3β hyperactivity in urinary exfoliated cells predicts progression of diabetic kidney disease
- (2019) Xianhui Liang et al. KIDNEY INTERNATIONAL
- US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States
- (2019) Rajiv Saran et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?
- (2019) Claire C J Dekkers et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
- (2019) Hiddo J L Heerspink et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Unraveling Cardiovascular Risk in Renal Patients: A New Take on Old Tale
- (2019) Michele Provenzano et al. Frontiers in Cell and Developmental Biology
- Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics
- (2018) Jennifer B. Green et al. AMERICAN HEART JOURNAL
- Update on Diabetic Nephropathy: Core Curriculum 2018
- (2018) Kausik Umanath et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension
- (2018) Grant R. Budas et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Semaglutide Treatment and Renal Function in the SUSTAIN 6 Trial
- (2018) TINA VILSBØLL et al. DIABETES
- Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
- (2018) M. ANGELYN BETHEL et al. DIABETES
- ASK1 inhibitor treatment suppresses p38/JNK signalling with reduced kidney inflammation and fibrosis in rat crescentic glomerulonephritis
- (2018) Liv A. Amos et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial
- (2018) Katherine R Tuttle et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Cardiorenal prognosis by residual proteinuria level in diabetic chronic kidney disease: pooled analysis of four cohort studies
- (2018) Roberto Minutolo et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
- (2018) Katherine R Tuttle et al. Lancet Diabetes & Endocrinology
- Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways
- (2018) Habib Yaribeygi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- ASK1 contributes to fibrosis and dysfunction in models of kidney disease
- (2018) John T. Liles et al. JOURNAL OF CLINICAL INVESTIGATION
- GLP-1 receptor agonists, CKD, and eGFR trajectory
- (2018) Michaël J B van Baar et al. Lancet Diabetes & Endocrinology
- Semaglutide Treatment and Renal Function in the SUSTAIN 6 Trial
- (2018) Irene Hramiak et al. Canadian Journal of Diabetes
- Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease
- (2018) Akira Nishiyama HYPERTENSION RESEARCH
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
- (2018) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
- (2018) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial
- (2018) Dick de Zeeuw et al. Lancet Diabetes & Endocrinology
- Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury–Mediated Chronic Kidney DiseaseNovelty and Significance
- (2017) Lionel Lattenist et al. HYPERTENSION
- A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy
- (2017) Shigehiro Katayama et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the Treatment of Diabetic Nephropathy
- (2017) Liad Hinden et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
- (2017) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
- (2017) Francesca Cinti et al. Drug Design Development and Therapy
- Vascular Adhesion Protein-1: A Cell Surface Amine Oxidase in Translation
- (2017) Marko Salmi et al. ANTIOXIDANTS & REDOX SIGNALING
- Cannabinoid receptors in the kidney
- (2016) Deanne H. Hryciw et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
- (2016) Ofri Mosenzon et al. DIABETES CARE
- JAK inhibition in the treatment of diabetic kidney disease
- (2016) Frank C. Brosius et al. DIABETOLOGIA
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- (2016) T. D. Filippatos et al. EXPERT OPINION ON PHARMACOTHERAPY
- Exogenous kallikrein protects against diabetic nephropathy
- (2016) Wenjuan Liu et al. KIDNEY INTERNATIONAL
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming
- (2016) Sebastian Zimmer et al. Science Translational Medicine
- Elevated cannabinoid receptor 1 and G protein-coupled receptor 55 expression in proximal tubule cells and whole kidney exposed to diabetic conditions
- (2015) Kayte A Jenkin et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- ASK1 Inhibitor Halts Progression of Diabetic Nephropathy inNos3-Deficient Mice
- (2015) Greg H. Tesch et al. DIABETES
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
- (2015) George L. Bakris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
- (2015) Jesper Lau et al. JOURNAL OF MEDICINAL CHEMISTRY
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets
- (2015) Stephanie Toth-Manikowski et al. Journal of Diabetes Research
- Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
- (2014) Erin E. Mulvihill et al. ENDOCRINE REVIEWS
- Cellular Cholesterol Transport Proteins in Diabetic Nephropathy
- (2014) Joseph G. S. Tsun et al. PLoS One
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Cyclodextrin Protects Podocytes in Diabetic Kidney Disease
- (2013) S. Merscher-Gomez et al. DIABETES
- Inhibition of Renal Glucose Reabsorption: A Novel Strategy for Achieving Glucose Control in Type 2 Diabetes Mellitus
- (2013) Muhammad Abdul-Ghani et al. Endocrine Practice
- Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy
- (2013) Michal Herman-Edelstein et al. JOURNAL OF LIPID RESEARCH
- Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
- (2013) M. Afkarian et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Epidemiology of Diabetic Kidney Disease
- (2013) Anne T. Reutens MEDICAL CLINICS OF NORTH AMERICA
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
- (2012) Lars Bärfacker et al. ChemMedChem
- How Does TGF-β Mediate Tubulointerstitial Fibrosis?
- (2012) Leslie Gewin et al. SEMINARS IN NEPHROLOGY
- LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects
- (2011) P. Barrington et al. DIABETES OBESITY & METABOLISM
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
- (2011) R. Grempler et al. DIABETES OBESITY & METABOLISM
- Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors
- (2011) Vincent Mascitti et al. JOURNAL OF MEDICINAL CHEMISTRY
- Distinct Actions of Endothelin A-Selective Versus Combined Endothelin A/B Receptor Antagonists in Early Diabetic Kidney Disease
- (2011) M. A. Saleh et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Regulation of Blood Pressure and Salt Homeostasis by Endothelin
- (2011) Donald E. Kohan et al. PHYSIOLOGICAL REVIEWS
- Molecular Mechanism of Cyclodextrin Mediated Cholesterol Extraction
- (2011) Cesar A. López et al. PLoS Computational Biology
- Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein
- (2010) Wolfgang Glaesner et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes
- (2010) M. A. Saleh et al. DIABETOLOGIA
- Endothelin-1 Increases Glomerular Permeability and Inflammation Independent of Blood Pressure in the Rat
- (2010) Mohamed A. Saleh et al. HYPERTENSION
- Endothelin-1 Increases Collagen Accumulation in Renal Mesangial Cells by Stimulating a Chemokine and Cytokine Autocrine Signaling Loop
- (2010) Michael S. Simonson et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of Canagliflozin, a NovelC-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus(1)
- (2010) Sumihiro Nomura et al. JOURNAL OF MEDICINAL CHEMISTRY
- Avosentan for Overt Diabetic Nephropathy
- (2010) J. F.E. Mann et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Endothelin type A and B receptors in the control of afferent and efferent arterioles in mice
- (2010) Janice Schildroth et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
- (2010) Ulrich Werner et al. REGULATORY PEPTIDES
- Serum vascular adhesion protein-1 is increased in acute and chronic hyperglycemia
- (2009) Hung-Yuan Li et al. CLINICA CHIMICA ACTA
- Protective effect of selenite on renal ischemia/reperfusion injury through inhibiting ASK1–MKK3–p38 signal pathway
- (2009) Yan Wang et al. REDOX REPORT
- Serum vascular adhesion protein-1 is higher in subjects with early stages of chronic kidney disease
- (2008) Mao-Shin Lin et al. CLINICAL BIOCHEMISTRY
- Enhanced Expression of Janus Kinase-Signal Transducer and Activator of Transcription Pathway Members in Human Diabetic Nephropathy
- (2008) C. C. Berthier et al. DIABETES
- Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
- (2008) Wei Meng et al. JOURNAL OF MEDICINAL CHEMISTRY
- (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors
- (2008) L. Thomas et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Role of apoptosis signal-regulating kinase 1 in complement-mediated glomerular epithelial cell injury
- (2008) Guohui Ren et al. MOLECULAR IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now